Journal
MOLECULAR CANCER
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12943-021-01371-1
Keywords
Liquid biopsy; Circulating nucleic acid; ctDNA; ctRNA; miRNA; lncRNA; Therapy monitoring; minimal residual disease (MRD); Early-stage non-small cell lung cancer (NSCLC)
Categories
Funding
- 2020 Karmanos Cancer Institute Cancer Immunology and Immunotherapy Pilot Award [P30 CA022453]
Ask authors/readers for more resources
Liquid biopsy has become a valuable diagnostic tool for advanced NSCLC, with ctDNA analysis being a key method for identifying targetable mutations. Monitoring ctDNA in plasma can help assess treatment response and residual disease burden, and new methods like miRNA and lncRNA are also being explored for their potential in NSCLC diagnosis and monitoring.
Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has been shown to increase the chances of identifying the presence of targetable mutations and has been adopted by many clinicians owing to its low risk. Serial monitoring of ctDNA may also help assess the treatment response or for monitoring relapse. As the presence of detectable plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to quantify plasma ctDNA to assess minimal residual disease (MRD) in early-stage resected NSCLC. Most data on utilizing liquid biopsy for monitoring MRD in early-stage NSCLC are from small-scale studies using ctDNA. Here, we review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs (miRNA) and long non-coding (lncRNA).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available